Clinical Trials
37 trialsNCT00577278 2024-02-16
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Phase 2 Completed
NCT00031642 2023-12-27
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
University of Nebraska
Phase 1/2 Completed
NCT00168727 2023-08-23
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed
NCT01811368 2022-11-30
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Unknown
NCT00493467 2022-09-15
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01549886 2021-10-04
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT01448928 2021-10-01
ZEVALIN-DUI
Spectrum Pharmaceuticals, Inc
Completed
NCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00491491 2020-08-31
Zevalin-beam for Aggressive Lymphoma
Sheba Medical Center
Phase 3 Completed
NCT00582166 2019-12-13
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
University of Wisconsin, Madison
Phase 2 Terminated
NCT00089284 2019-08-14
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Northwestern University
Phase 1/2 Terminated
NCT00392691 2019-05-15
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Phase 1 Completed
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00644371 2017-03-27
Z-RIC-Allo
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00062114 2016-07-06
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00646750 2016-02-15
Z-BEAM LDGGB
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT00005592 2015-10-21
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Alabama at Birmingham
Phase 2 Completed
NCT00319332 2015-04-17
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
GlaxoSmithKline
Phase 3 Withdrawn
NCT00220285 2014-12-30
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Bayer
Phase 2 Completed
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed
NCT00521560 2013-02-15
escZ-BEAM
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Phase 2 Completed
NCT00017381 2013-01-09
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed
NCT00463463 2012-07-12
Zevalin
Soroka University Medical Center
Phase 3 Unknown
NCT00186589 2012-06-06
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Stanford University
Phase 1 Completed
NCT00058292 2012-06-01
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Northwestern University
Phase 1 Completed
NCT01479387 2011-11-24
ZEVALIN-SDUI
Bayer
Completed
NCT00193440 2010-12-30
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00271050 2010-12-21
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
The Cleveland Clinic
Phase 1 Completed
NCT01164696 2010-08-24
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Bayer
Completed
NCT00354822 2009-09-18
Z0105
A.O. Ospedale Papa Giovanni XXIII
Phase 2 Terminated
NCT00807196 2008-12-11
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Maisonneuve-Rosemont Hospital
Phase 1/2 Unknown
NCT00185393 2008-12-01
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Bayer
Phase 3 Completed
NCT00438581 2007-02-27
Zevalin
McGill University
Phase 2 Unknown
NCT00057343 2006-09-12
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
Biogen
Phase 3 Terminated